Chairs G. Antoniou (UK), D. Papadatos-Pastos (UK)
08.50-09.10 The treatment of ALK / ROS1 NSCLC: An update P. Christopoulos (DE)
09.10-09.30 EGFR mutant NSCLC: Identifying the optimal first-line treatment E. Vorrias (CY)
09.30-09.50 MET, HER2, RET and NTRK alterations or RET resistance Th. Tegos (GR)
09.50-10.10 KRAS-mutant NSCLC beyond G12C O. Fiste (GR)
10.10-10.20 Discussion
Chairs: E. Vorrias (CY), F. Koinis (GR)
What Comes After Immunotherapy? Strategies Beyond Progression in Metastatic NSCLC G. Tsakonas (CY)
Chairs: D. Papadatos-Pastos (UK), G. Imseeh (UK), N. Panagiotopoulos (UK)
11.20-11.40 Redefining Cure in NSCLC: Where Are We in 2026? / From Surgery
to Systemic Therapy: The New Curative Continuum in NSCLC G. Evangelou (GR)
11.40-12.00 Radiotherapy in the Curative Setting: From Stand-Alone to Strategic Partner / When Surgery Is Not the Answer: Alternative Curative Strategies K. Ferentinos (CY)
12.00-12.20 Case 1 - Neoadjuvant treatment IIIA D. Ragias (GR)
12.20-12.40 Case 2 - Borderline / perioperative resectable V. Aidarinis (GR)
12.40-13.00 Case 3 - Unresectable patient, Stage III A.M. Shiarli (CY)
13.00-13.20 Tumor Board: N. Konstantinidis (GR), K. Xydis (GR), E. Vorrias (CY), Ch. Charalambous (CY), G. Maravelis (GR), D. Vassos (GR), D. Papadatos-Pastos (UK)
Chairs: D. Papadatos-Pastos (UK), G. Imseeh (UK)
Long-term survival data in mNSCLC P. Katsaounis (GR)
Sponsored by MSD
Chairs: F. I. Dimitrakopoulos (GR), F. Koinis (GR)
Three Years of the Thoracic Research Network: From Connection
to Consequence F. I. Dimitrakopoulos (GR), F. Koinis (GR)
• Biomarkers
• Translational Research
Panel: A. Kotsakis (GR), K. Ferentinos (CY), E. Vorrias (CY), G. Tsakonas (CY),
N. Panagiotopoulos (UK), G. Antoniou (UK), E. Boleti (UK), Th. Tegos (GR),
Ch. Charalambous (CY), A.M. Shiarli (CY), G. Evangelou (GR), G. Kallergi (GR),
N. Asimakopoulou (GR), I. Pateras (GR), D. Papadatos-Pastos (UK), A. Koulouris (SE),
E. Fergadis (GR)
Chairs: F. Koinis (GR), G. Gomatou (GR)
17.00-17.30 The Evolving Landscape of Daiichi Sankyo’s Pipeline in Lung Cancer D. Krikelis (GR)
17.30-18.00 Johnson & Johnson: Lung Cancer’s Portfolio Innovation Across the Treatment Landscape A. Theodorou (GR)
Chairs: S. Agelaki (GR), F.I. Dimitrakopoulos (GR)
18.00-18.20 Modern Treatment Algorithm of Extensive-Stage SCLC I. Mountzios (GR)
18.20-18.40 Case 1 - Experience from Tarlatamab S. Arora (UK)
18.40-19.00 Case 2 - Experience from Lurbinectedin Ch. Charalambous (CY)
19.00-19.20 Case 3 - Mesothelioma M. Pandi (GR)
Panel Discussants: F. Koinis (GR), N. Panagiotopoulos (UK), G. Gomatou (GR), Ch. Charalambous (CY)
Chairs: A. Kotsakis (GR), F.I. Dimitrakopoulos (GR)
Cellular Therapies in Lung Cancer: From Biological Promise to Clinical Reality G. Fotopoulos (US)
Chairs: Ch. Charalambous (CY), V. Georgoulias (GR)
08.30-08.50 Targeted Therapies against EGFR in Early NSCLC:
Recent Advances E. Fergadis (GR)
08.50-09.10 Targeting ALK in Early-Stage NSCLC N. Asimakopoulou (GR)
09.10-09.30 Beyond EGFR and ALK in Early-Stage NSCLC A. Boukouris (GR)
09.30-09.50 Case 1 - EGFR mutant E. Koustas (GR)
09.50-10.10 Case 2 - EGFR-mutated NSCLC with disease progression on first-line therapy M. Papadakis (GR)
Tumor Board: P. Christopoulos (DE), F. Koinis (GR), D. Papadatos-Pastos (UK)
Chairs: P. Constantoulakis (GR), G. Tsakonas (CY)
10.40-11.05 ctDNA in early-stage disease F. Koinis (GR)
11.05-11.30 Plasma-first strategies: Blood-based Biomarkers useful in NSCLC management E. Papadopoulou (GR)
Panel Discussants: A. Kotsakis (GR), D. Papadatos-Pastos (UK), Ch. Charalambous (CY)
Chairs: A. Koutsopoulos (GR), P. Constantoulakis (GR)
11.40-12.00 Synthetic lethality and epigenetics A. Klinakis (GR)
12.00-12.20 Tumor microenvironment in NSCLC and molecular landscape I. Pateras (GR)
12.20-12.40 Who Really Benefits from Immunotherapy? Biomarkers Beyond PD-L1 in Metastatic NSCLC A. Koulouris (SE)
12.40-13.00 Discussion
Chairs: P. Christopoulos (DE), I. Pateras (GR)
Advancing Lung Cancer Staging - IASLC Recommendations and Bioinformatics M. Allgäuer (DE)
Chairs: F. Koinis (GR), F.I. Dimitrakopoulos (GR)
• Real World Data & Registries
• Clinical Trials
Panel: A. Kotsakis (GR), K. Ferentinos (CY), E. Vorrias (CY), G. Tsakonas (CY), N. Panagiotopoulos (UK), G. Antoniou (UK), E. Boleti (UK), Th. Tegos (GR), Ch. Charalambous (CY), A.M. Shiarli (CY), G. Evangelou (GR), G. Kallergi (GR), N. Asimakopoulou (GR), I. Pateras (GR), D. Papadatos-Pastos (UK), A. Koulouris (SE), E. Fergadis (GR)
Chairs: G. Stratakos (GR), G. Maravelis (GR)
16.00-16.20 Current Status and Future Perspectives of Interventional Pulmonology in Lung Cancer F. Sampsonas (GR)
16.20-16.40 Creating Opportunity: How Interventional Pulmonology Shapes Treatment Pathways N. Panagiotopoulos (UK)
16.40-17.00 Stereotactic Radiotherapy: Timing, Biology and Integration with Systemic Therapy A.M. Shiarli (CY)
17.00-17.10 Case Discussion V. Adamou (CY)
Chairs: S. Agelaki (GR), P. Savvides (US)
17.30-17.50 Key ADC targets: TROP2, HER3, B7-H3 and Beyond E. Boleti (UK)
17.50-18.10 Resistance to ADCs and Rational Combinations: What Comes Next? G. Evangelou (GR)
18.10-18.30 Case 1 - Enhertu in HER2-Mutant NSCLC K. Baines (UK)
18.30-18.50 Case 2 - Datopotamab P. Savvides (US)
18.50-19.00 Tumor Board: F. Koinis (GR), D. Papadatos-Pastos (UK), Th. Tegos (GR), E. Vorrias (CY)
Chairs: C. Baxevanis (GR), O. Tsitsilonis (GR)
19.00-19.25 Beyond KRAS G12C F. Skoulidis (US)
19.25-19.50 Cancer Vaccines in Lung Cancer: Are We Finally Ready? V. Karantza (US)
19.50-20.00 Discussion




















